Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Melanoma 11Lung Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Neoplasms 5Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Urinary Bladder Neoplasms 1Uncommon Pathological Types of Lung Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Sexual Dysfunction, Physiological 1Sarcopenia 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1NSCLC 1Motor Activity 1Lung Squamous Cell Carcinoma Stage IV 1Lung Diseases, Interstitial 1Liver Diseases 1Kidney Neoplasms 1

Interventions

Blood Specimen Collection 2toripalimab 1tislelizumab 1sintilimab 1pembrolizumab 1lenvatinib 1gadolinium ethoxybenzyl DTPA 1camrelizumab 1User-Centered Design 1Standard of Care 1Shadowing Technique, Histology 1Nivolumab 1Neuropsychological Tests 1Lead 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Liver Diseases × pembrolizumab × Clear all
NCT04627012 2024-03-06

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Sun Yat-sen University

Completed
600 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡